According to the Complaint, Replimune Group, Inc. was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies. This class action was filed against Replimune and two of its Officers.

Pertinent to this action is the Company’s IGNYTE trial, the purpose of which is to treat skin cancer. The Complaint alleges that Defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Defendants recklessly overstated the IGNYTE trial’s prospects, given material issues that defendants knew or should have known of, which resulted in the FDA deeming the IGNYTE trial inadequate and not well-controlled; and (2) as a result, Defendants’ statements about Replimune’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all times.